JP2005527492A - メラノコルチン受容体アゴニスト - Google Patents
メラノコルチン受容体アゴニスト Download PDFInfo
- Publication number
- JP2005527492A JP2005527492A JP2003561604A JP2003561604A JP2005527492A JP 2005527492 A JP2005527492 A JP 2005527492A JP 2003561604 A JP2003561604 A JP 2003561604A JP 2003561604 A JP2003561604 A JP 2003561604A JP 2005527492 A JP2005527492 A JP 2005527492A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- compound
- aryl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCC(C(N(C)CC(C)(C)CN(C*C)C(*)(CC)C(C)(C)*(C)(C)C)=O)N(*)C(C)(C)* Chemical compound CCC(C(N(C)CC(C)(C)CN(C*C)C(*)(CC)C(C)(C)*(C)(C)C)=O)N(*)C(C)(C)* 0.000 description 16
- ZEPVGQGDVKVDGY-UHFFFAOYSA-N CC(C(C1)N(C)Cc2c1ccc(O)c2)=O Chemical compound CC(C(C1)N(C)Cc2c1ccc(O)c2)=O ZEPVGQGDVKVDGY-UHFFFAOYSA-N 0.000 description 1
- QPMBNMZRZROBST-UHFFFAOYSA-N CC(C)(C)OC(N1C(C)(CC(NC(Cc(cc2)ccc2Cl)C(OC)=O)=O)c2ccccc2C1)=O Chemical compound CC(C)(C)OC(N1C(C)(CC(NC(Cc(cc2)ccc2Cl)C(OC)=O)=O)c2ccccc2C1)=O QPMBNMZRZROBST-UHFFFAOYSA-N 0.000 description 1
- LHBZYQJYJWIKMM-VGOKPJQXSA-N CC(C)(C)OC(N1C(C)(CC(N[C@H](Cc(cc2)ccc2Cl)C(O)=O)=O)c2ccccc2C1)=O Chemical compound CC(C)(C)OC(N1C(C)(CC(N[C@H](Cc(cc2)ccc2Cl)C(O)=O)=O)c2ccccc2C1)=O LHBZYQJYJWIKMM-VGOKPJQXSA-N 0.000 description 1
- DQVHIQQUGLBAOE-UHFFFAOYSA-N CC(C)(C)OC(N1C(CC(O)=O)c2ccccc2CC1)=O Chemical compound CC(C)(C)OC(N1C(CC(O)=O)c2ccccc2CC1)=O DQVHIQQUGLBAOE-UHFFFAOYSA-N 0.000 description 1
- XCZDALCUPUEVOT-LLVKDONJSA-N CC(C)C([C@@H]1NCc2c1cccc2)=O Chemical compound CC(C)C([C@@H]1NCc2c1cccc2)=O XCZDALCUPUEVOT-LLVKDONJSA-N 0.000 description 1
- GSXDYZPMLCQEKT-IADGFXSZSA-N CC(C)CC(CC1)(CCN1C(C)C)N(CC1)CCN1C([C@@H](Cc(cc1)ccc1Cl)NC(CC1NCc2c1cccc2)=O)=O Chemical compound CC(C)CC(CC1)(CCN1C(C)C)N(CC1)CCN1C([C@@H](Cc(cc1)ccc1Cl)NC(CC1NCc2c1cccc2)=O)=O GSXDYZPMLCQEKT-IADGFXSZSA-N 0.000 description 1
- ITVSAHWUFMBQHK-GFCCVEGCSA-N CC([C@@H](C1)N(C)Cc2c1cccc2)=O Chemical compound CC([C@@H](C1)N(C)Cc2c1cccc2)=O ITVSAHWUFMBQHK-GFCCVEGCSA-N 0.000 description 1
- NQKOOIJJWDMYSO-UHFFFAOYSA-N CCN(CC)CC1(CCCC1)N(CC1)CCN1C(C(Cc(cc1)ccc1Cl)NC(C1NCc2ccccc2C1)=O)=O Chemical compound CCN(CC)CC1(CCCC1)N(CC1)CCN1C(C(Cc(cc1)ccc1Cl)NC(C1NCc2ccccc2C1)=O)=O NQKOOIJJWDMYSO-UHFFFAOYSA-N 0.000 description 1
- BVYMFRPUYTXWSJ-UHFFFAOYSA-N CCOC(CC1c2ccccc2CCCC1CCC(OC(C)(C)C)=O)=O Chemical compound CCOC(CC1c2ccccc2CCCC1CCC(OC(C)(C)C)=O)=O BVYMFRPUYTXWSJ-UHFFFAOYSA-N 0.000 description 1
- CMNLNCAHSRIGNB-UHFFFAOYSA-N CN(C1)C(CC(O)=O)c2c1cccc2 Chemical compound CN(C1)C(CC(O)=O)c2c1cccc2 CMNLNCAHSRIGNB-UHFFFAOYSA-N 0.000 description 1
- FECOKXYSVFVXRX-VOTSOKGWSA-N COC(/C=C/c1c(C=O)cccc1)=O Chemical compound COC(/C=C/c1c(C=O)cccc1)=O FECOKXYSVFVXRX-VOTSOKGWSA-N 0.000 description 1
- NGXWJSXFCKTYLI-BQYQJAHWSA-N COC(/C=C/c1ccccc1C=O)=[O]=C Chemical compound COC(/C=C/c1ccccc1C=O)=[O]=C NGXWJSXFCKTYLI-BQYQJAHWSA-N 0.000 description 1
- SBTPNLFSCKSEDO-UHFFFAOYSA-N COC(CC1N(Cc2ccccc2)Cc2ccccc12)=O Chemical compound COC(CC1N(Cc2ccccc2)Cc2ccccc12)=O SBTPNLFSCKSEDO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35120002P | 2002-01-23 | 2002-01-23 | |
| PCT/US2003/000033 WO2003061660A1 (en) | 2002-01-23 | 2003-01-21 | Melanocortin receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527492A true JP2005527492A (ja) | 2005-09-15 |
| JP2005527492A5 JP2005527492A5 (enExample) | 2006-02-02 |
Family
ID=27613471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003561604A Pending JP2005527492A (ja) | 2002-01-23 | 2003-01-21 | メラノコルチン受容体アゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7314879B2 (enExample) |
| EP (1) | EP1469851B1 (enExample) |
| JP (1) | JP2005527492A (enExample) |
| AT (1) | ATE342057T1 (enExample) |
| CA (1) | CA2473036A1 (enExample) |
| DE (1) | DE60308996T2 (enExample) |
| ES (1) | ES2274201T3 (enExample) |
| WO (1) | WO2003061660A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008508242A (ja) * | 2004-07-29 | 2008-03-21 | サノフイ−アベンテイス | アミノ−トロパン誘導体、その調製及び治療上のその使用 |
| WO2017022733A1 (ja) * | 2015-08-04 | 2017-02-09 | アステラス製薬株式会社 | ピペラジン誘導体 |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
| US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| JP2005504043A (ja) | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク． | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7354923B2 (en) | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| TW200504033A (en) | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
| US7550602B1 (en) | 2004-01-14 | 2009-06-23 | Palatin Technologies, Inc. | Small molecule compositions for sexual dysfunction |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| BRPI0616463A2 (pt) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
| US7652024B2 (en) | 2005-10-18 | 2010-01-26 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0624987D0 (en) | 2006-12-14 | 2007-01-24 | Acure Pharma Ab | Novel aminoguanidines as melanocortin receptor ligands |
| EP2300036B1 (en) * | 2008-06-09 | 2017-04-05 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
| US8227628B2 (en) | 2008-07-09 | 2012-07-24 | Northwestern University | Method of synthesizing acetonide-protected catechol-containing compounds and intermediates produced therein |
| JP5514831B2 (ja) | 2008-11-17 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療のための置換二環式アミン |
| EP2413701A4 (en) * | 2009-03-31 | 2012-10-03 | Univ Vanderbilt | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGUES AS GLYT1 INHIBITORS, METHODS OF MAKING THEM AND USE THEREOF IN THE TREATMENT OF PSYCHIATRIC DISORDERS |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| SG186885A1 (en) | 2010-06-04 | 2013-02-28 | Albany Molecular Res Inc | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| EP2579873A4 (en) | 2010-06-11 | 2013-11-27 | Merck Sharp & Dohme | NOVEL PROLYLCARBOXYPEPTIDASE HEMMER |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| HUE047346T2 (hu) | 2010-07-16 | 2020-04-28 | Univ Columbia | Aldóz reduktáz inhibitorok és alkalmazásuk |
| EP2632464B1 (en) * | 2010-10-29 | 2015-04-29 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2012100342A1 (en) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| ES2847934T3 (es) | 2013-06-05 | 2021-08-04 | Shanghai Lumosa Therapeutics Co Ltd | Nuevos compuestos que tienen actividades triples de trombólisis, antitrombóticos y captadores de radicales, y síntesis, nanoestructura y uso de los mismos |
| AR105654A1 (es) * | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| PT3352754T (pt) | 2016-06-21 | 2020-12-07 | Univ Columbia | Inibidores da aldose redutase e métodos de seu uso |
| PT3489231T (pt) | 2016-07-19 | 2021-07-14 | Astellas Pharma Inc | Derivado de piperazina |
| IL272246B1 (en) | 2017-07-28 | 2025-09-01 | Applied Therapeutics Inc | Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia |
| EP3966320A4 (en) | 2019-05-07 | 2023-10-25 | University of Miami | TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS |
| US11590209B2 (en) | 2020-01-21 | 2023-02-28 | Palatin Technologies, Inc. | Use of bremelanotide in patients with controlled hypertension |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT72076A (en) | 1992-12-11 | 1996-03-28 | Merck & Co Inc | Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them |
| US6127381A (en) | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| AU742425B2 (en) * | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| US6294534B1 (en) * | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| CA2377369A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| JP2003528088A (ja) | 2000-03-23 | 2003-09-24 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| WO2001070337A1 (en) | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| JP2004506687A (ja) | 2000-08-23 | 2004-03-04 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| WO2002059108A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Melanocortin receptor agonists |
| CA2433025A1 (en) | 2001-01-23 | 2002-08-01 | Chaoyu Xie | Substituted piperidines/piperazines as melanocortin receptor agonists |
| JP2004524297A (ja) | 2001-01-23 | 2004-08-12 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニスト |
| CA2437594A1 (en) | 2001-03-02 | 2002-09-12 | Graham S. Poindexter | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| EP1465867A1 (en) * | 2001-10-09 | 2004-10-13 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
-
2003
- 2003-01-21 EP EP03701964A patent/EP1469851B1/en not_active Expired - Lifetime
- 2003-01-21 US US10/500,476 patent/US7314879B2/en not_active Expired - Fee Related
- 2003-01-21 CA CA002473036A patent/CA2473036A1/en not_active Abandoned
- 2003-01-21 AT AT03701964T patent/ATE342057T1/de not_active IP Right Cessation
- 2003-01-21 JP JP2003561604A patent/JP2005527492A/ja active Pending
- 2003-01-21 DE DE60308996T patent/DE60308996T2/de not_active Expired - Fee Related
- 2003-01-21 ES ES03701964T patent/ES2274201T3/es not_active Expired - Lifetime
- 2003-01-21 WO PCT/US2003/000033 patent/WO2003061660A1/en not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008508242A (ja) * | 2004-07-29 | 2008-03-21 | サノフイ−アベンテイス | アミノ−トロパン誘導体、その調製及び治療上のその使用 |
| WO2017022733A1 (ja) * | 2015-08-04 | 2017-02-09 | アステラス製薬株式会社 | ピペラジン誘導体 |
| JPWO2017022733A1 (ja) * | 2015-08-04 | 2018-05-31 | アステラス製薬株式会社 | ピペラジン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1469851A1 (en) | 2004-10-27 |
| US20050075344A1 (en) | 2005-04-07 |
| DE60308996T2 (de) | 2007-05-10 |
| DE60308996D1 (de) | 2006-11-23 |
| CA2473036A1 (en) | 2003-07-31 |
| EP1469851B1 (en) | 2006-10-11 |
| ATE342057T1 (de) | 2006-11-15 |
| US7314879B2 (en) | 2008-01-01 |
| WO2003061660A1 (en) | 2003-07-31 |
| ES2274201T3 (es) | 2007-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527492A (ja) | メラノコルチン受容体アゴニスト | |
| US7157463B2 (en) | Substituted piperidines/piperazines as melanocortin receptor agonists | |
| US7169777B2 (en) | Melanocortin receptor agonists | |
| US7186715B2 (en) | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | |
| JP2004524297A5 (enExample) | ||
| US6410548B2 (en) | Spiropiperidine derivatives as melanocortin receptor agonists | |
| EP1085869A1 (en) | Spiropiperidine derivatives as melanocortin receptor agonists | |
| IE904310A1 (en) | Heterocyclic substituted acylaminothiazoles, their preparation and pharmaceutical compositions containing them | |
| US7592359B2 (en) | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | |
| EP1797040A1 (en) | Muscarinic receptor antagonists | |
| AU2003202852A1 (en) | Melanocortin receptor agonists | |
| AU2002235323A1 (en) | Substituted piperidines/piperazines as melanocortin receptor agonists | |
| AU2002235322A1 (en) | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | |
| AU2002235324A1 (en) | Melanocortin receptor agonists | |
| AU2002246969A1 (en) | Melanocortin receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051206 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080911 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090526 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090527 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091020 |